No Data
Nippon Shinyaku To Go Ex-Dividend On September 27th, 2024 With 62 JPY Dividend Per Share
September 26th (Japan Standard Time) - $Nippon Shinyaku(4516.JP)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 62 JPY dividend per share.
Nisshin Pharmaceutical, etc. [stocks with attractive taste based on volume changes]
Stock Closing Price Change from Previous Day Volume*＜4918＞Ivy 318 20 1291100*＜8143＞Lapinu 237 2 78900*＜6552＞GameWith 246 50 1099700*＜2180＞Sunyside 590 44 697800*＜4516＞Nisshin Yakuhin 3866 478 2115800*＜7523＞Earl Vivian 1045
Nisshin Yakuhin, Tohoku Shinsha, CYBOZU, etc.
Rakuten Bank (5838) fell significantly by 216 to 2869. Today, the insurance, banking, and other financial sectors are among the top in terms of industry-specific decline rates. The yield on newly issued 10-year government bonds fell below 0.8% for the first time since August 5, becoming a negative factor for financial related stocks. BOJ Governor Ueda mentioned in a speech on the previous day that the determination regarding future additional rate hikes should be done 'timely and appropriately', and it is necessary to 'carefully confirm' the trends in the financial markets and the overseas economic situation. There is 'such temporal leeway'. Additional rate hikes.
Hot stocks digest (morning session): Nisshin Pharmaceutical, CYBOZU, Shiseido Company,Limited Sponsored ADR, etc.
Nisshin Pharma <4516>: 3830 yen (+442 yen) significantly extended. J&J has announced that it has obtained manufacturing and sales approval for the combination drug "Yubanshi Combination Tablets", which combines the endothelin receptor antagonist macitentan 10mg and the phosphodiesterase 5 inhibitor tadalafil 40mg, for the treatment of pulmonary arterial hypertension. Positive movements towards expanding into the field of pulmonary hypertension, which is positioned as one of the areas of focus, are taking the lead. shiseido company,limited sponsored adr <4911>
Nisshin Pharmaceutical's stock soared significantly as J&J obtained manufacturing and marketing approval for pulmonary arterial hypertension.
Nisshinyaku <4516> is sharply rising. J&J announced that it has obtained manufacturing and marketing approval for the combination tablet "Yubanshi Combination Tablet," which contains the endothelin receptor antagonist macitentan 10mg and the phosphodiesterase 5 inhibitor tadalafil 40mg, for the treatment of pulmonary arterial hypertension. There is a positive movement towards expanding into the field of pulmonary hypertension, which is positioned as one of the areas of focus.
Volume change rate ranking (10 o'clock) - Celebs, ALiNK, etc. are ranked.
※In the volume change rate ranking, it is possible to understand the interest of market participants such as trends in speculation by comparing the average volume of the last 5 days with the volume on the delivery day. ■ Volume change rate top [As of 10:32 on September 25] (Comparison of average volume over the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Price Change Rate＜3696＞ Celes 775,200 118,780 200.39% -0.1115
No Data
No Data